文献速递肝病

乙型肝炎病毒通过抑制NF-κB通路和ROS产生抑制LPS诱导的NLRP3炎症小体活化和IL-1β生成

HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production.
PubMed 文献 · J Hepatol · 2016-12-24

本研究探讨乙型肝炎病毒(HBV)是否影响NLRP3炎症小体信号通路及其机制。结果显示,慢性HBV感染通过HBeAg抑制LPS诱导的NLRP3和pro-IL-1β表达及IL-1β成熟,机制涉及抑制NF-κB信号通路和活性氧(ROS)产生;该抑制在慢性乙型肝炎(CHB)和肝细胞癌患者癌旁组织中得到验证,并可能增加小鼠对鼠伤寒沙门菌感染的易感性。

要点

  • 慢性HBV感染抑制LPS诱导的Kupffer细胞NLRP3和pro-IL-1β表达及IL-1β成熟。
  • HBeAg通过抑制NF-κB通路和ROS产生介导该抑制作用。
  • 慢性HBV感染可能通过抑制NLRP3炎症小体活化增加小鼠对鼠伤寒沙门菌感染的易感性。

核心结论

  • HBeAg通过抑制NF-κB通路和ROS产生抑制LPS诱导的NLRP3炎症小体活化和IL-1β生成。

研究设计与样本

  • 研究采用Western blot、定量RT-PCR、流式细胞术和免疫荧光评估HBV对LPS诱导的NLRP3炎症小体活化的抑制,并在慢性乙型肝炎和肝细胞癌患者癌旁组织及小鼠模型中验证。

主要发现

  • LPS刺激后Kupffer细胞表达的NLRP3和IL-1β显著增多,而慢性HBV感染抑制LPS诱导的NLRP3和pro-IL-1β表达以及IL-1β成熟。
  • 该抑制活性由HBeAg介导,涉及抑制NF-κB信号通路和ROS产生。
  • 通过比较HBeAg阳性或阴性患者癌旁组织中IL-1β和NLRP3相关蛋白水平,在慢性乙型肝炎和肝细胞癌患者中证实了HBeAg的抑制作用。
  • 慢性HBV感染可能通过抑制NLRP3炎症小体活化和IL-1β生成增加小鼠对鼠伤寒沙门菌感染的易感性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatitis B virus (HBV) has developed strategies to evade immune responses. However, the mechanisms involved remain unclear. The NLRP3 inflammasome plays crucial roles in antiviral host defense and its downstream factor IL-1β has been shown to inhibit HBV infection in vivo. This study aims to assess whether HBV can affect the NLRP3 inflammasome signaling pathways and shed light on the underlying mechanisms HBV utilizes to evade host innate immune responses. METHODS: HBV inhibition of the lipopolysaccharide (LPS)-induced NLRP3 inflammasome activation was evaluated by Western blot, quantitative RT-PCR, flow cytometry and immunofluorescence. RESULTS: Kupffer cells expressed significantly more NLRP3 and IL-1β after LPS stimulation; whereas, chronic HBV infection suppressed LPS-induced NLRP3 and pro-IL-1β expression as well as IL-1β maturation. This inhibitory activity is mediated by HBeAg, and is involved in the inhibition of NF-κB signal pathway and reactive oxygen species (ROS) production. The inhibitory effect of HBeAg was confirmed in patients with chronic hepatitis B (CHB) and hepatocellular carcinoma by comparing the levels of IL-1β and NLRP3-related proteins in para-carcinoma tissues from HBeAg-positive or negative patients. Moreover, chronic HBV infection increases the susceptibility of mice to S. typhimurium infection, possibly via inhibiting the NLRP3 inflammasome activation and IL-1β production. CONCLUSIONS: HBeAg inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing NF-κB pathway and ROS production. This finding provides a novel mechanism for HBV-mediated suppression of innate immune responses, and identifies new therapeutic targets for chronic HBV infection and related diseases. LAY SUMMARY: HBeAg suppresses LPS-induced NLRP3 inflammasome activation and IL-1β production in two ways, one is to repress NLRP3 and pro-IL-1β expression via inhibiting NF-κB phosphorylation, and the other is to repress caspase-1 activation and IL-1β maturation via inhibiting ROS production. This effect contributes to the HBV persistence and immune tolerance.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yu X, Lan P, Hou X, et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production. J Hepatol. 2016. PMID: 28027970. doi:10.1016/j.jhep.2016.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。